Holen Sie sich die Stockscreener-App
3.04
4.11%
0.12
Schlusskurs vom Vortag:
$2.92
Offen:
$2.9
24-Stunden-Volumen:
24.29M
Relative Volume:
6.01
Marktkapitalisierung:
$495.69M
Einnahmen:
-
Nettoeinkommen (Verlust:
$-175.43M
KGV:
-1.5403
EPS:
-1.9736
Netto-Cashflow:
$-143.28M
1W Leistung:
+7.04%
1M Leistung:
-18.28%
6M Leistung:
+38.81%
1J Leistung:
+78.82%
1-Tages-Spanne:
$2.82
$3.08
1-Wochen-Bereich:
$2.82
$3.15
52-Wochen-Spanne:
$1.26
$4.23
Cabaletta Bio Inc Stock (CABA) Company Profile
Firmenname
Cabaletta Bio Inc
Sektor
Branche
Telefon
(267) 759-3100
Adresse
2929 ARCH STREET, PHILADELPHIA, PA
Compare CABA vs VRTX, REGN, ARGX, ALNY, RVMD
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
CABA
Cabaletta Bio Inc
|
3.04 | 495.69M | 0 | -175.43M | -143.28M | -1.9736 |
VRTX
Vertex Pharmaceuticals Inc
|
491.34 | 124.70B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
632.90 | 66.35B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
887.18 | 55.17B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
291.37 | 38.90B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
182.08 | 38.71B | 742.00K | -1.37B | -1.07B | -7.0731 |
Cabaletta Bio Inc Stock (CABA) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-10-10 | Fortgesetzt | Jefferies | Buy |
| 2024-12-20 | Herabstufung | Evercore ISI | Outperform → In-line |
| 2024-12-19 | Herabstufung | Wells Fargo | Overweight → Equal Weight |
| 2024-10-10 | Eingeleitet | UBS | Buy |
| 2024-02-05 | Eingeleitet | Jefferies | Buy |
| 2023-11-29 | Eingeleitet | William Blair | Outperform |
| 2023-10-24 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2023-10-19 | Eingeleitet | Stifel | Buy |
| 2023-09-05 | Eingeleitet | Citigroup | Buy |
| 2023-07-18 | Eingeleitet | Guggenheim | Buy |
| 2023-01-27 | Hochstufung | Morgan Stanley | Equal-Weight → Overweight |
| 2022-08-30 | Herabstufung | Morgan Stanley | Overweight → Equal-Weight |
| 2021-12-08 | Eingeleitet | Wells Fargo | Overweight |
| 2021-10-19 | Fortgesetzt | Morgan Stanley | Overweight |
| 2021-06-30 | Eingeleitet | Mizuho | Buy |
| 2021-01-08 | Eingeleitet | Chardan Capital Markets | Buy |
| 2020-10-13 | Eingeleitet | H.C. Wainwright | Buy |
| 2019-11-19 | Eingeleitet | Cowen | Outperform |
| 2019-11-19 | Eingeleitet | Evercore ISI | Outperform |
| 2019-11-19 | Eingeleitet | Morgan Stanley | Overweight |
Alle ansehen
Cabaletta Bio Inc Aktie (CABA) Neueste Nachrichten
Cabaletta Bio: The Market Sold The EULAR News, I'm Buying (NASDAQ:CABA) - Seeking Alpha
Cabaletta Bio, Inc. Actuals & Estimates (NASDAQ:CABA) - TradingView
CABA Stock On Track For Best Day In 6 Months After Positive Early Results From Cell Therapy Trial - Stocktwits
CABA Forecast — Price Target — Prediction for 2027 - TradingView
Cabaletta Bio (CABA) upgraded to buy: Here's why - MSN
Cabaletta Bio(CABA) Stock Options Chain | Quotes & News - Moomoo
Cabaletta Bio, Inc.(NasdaqGS: CABA) added to S&P Biotechnology Select Industry Index - marketscreener.com
CABA - Finviz
Cabaletta Bio Inc (CABA) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
Cabaletta Bio Inc (CABA) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
Cabaletta Bio Inc (CABA) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
How Cabaletta Bio (CABA) Is Turning Rese-cel Enrollment and New Financing Into a Clearer Autoimmune Cell Therapy Setup - Insider Monkey
CABA Technical Analysis & Stock Price Forecast - Intellectia AI
5 Small Cap Stocks with Potential to Rise 1000 Percent - Insider Monkey
Cabaletta Bio Shareholders Approve Share Increase and Directors - The Globe and Mail
Cabaletta Bio (NASDAQ: CABA) doubles authorized common shares - Stock Titan
[Form 4] Cabaletta Bio, Inc. Insider Trading Activity - Stock Titan
Director at Cabaletta Bio (CABA) receives grant of 22,000 stock options - Stock Titan
Cabaletta Bio (CABA) director receives stock options for 22,000 shares at $3.22 - Stock Titan
Cabaletta Bio | 4: Statement of changes in beneficial ownership of securities-Director Bollard Catherine - Moomoo
Cabaletta Bio (CABA) director Catherine Bollard receives 22,000 stock options at $3.22 - Stock Titan
22,000 options granted to Cabaletta Bio (CABA) director Brun - Stock Titan
Cabaletta Bio | 4: Statement of changes in beneficial ownership of securities-Director Simon Mark - Moomoo
Cathie Wood's ARK Invest Joins Cellares' $277 Million Series D - Business Wire
CABA: Rese-cel delivers durable, safe remissions in myositis, supporting rapid outpatient adoption - TradingView
CABA: Rese-cel shows durable, safe, drug-free responses, enabling rapid outpatient adoption and expansion - TradingView
Cabaletta Bio Inc at Goldman Sachs Healthcare Conference Transcript - GuruFocus
Cabaletta Bio Inc. (CABA) A Top Penny Stock Eyeing Rese-Cel Commercial Launch for Autoimmune Diseases - Yahoo Finance
Jennison Associates LLC Increases Stake in Cabaletta Bio Inc - GuruFocus
Investors’ Stock Portfolio: Top 5 Penny Stocks To Buy - Insider Monkey
Prudential (NYSE: PRU) holds 24.3M shares of Cabaletta Bio (CABA), 11.4% - Stock Titan
H.C. Wainwright Maintains Cabaletta Bio(CABA.US) With Buy Rating, Maintains Target Price $16 - Moomoo
Jennison Associates (NASDAQ: CABA) holds 24.27M shares, 11.4% - Stock Titan
Morgan Stanley Maintains Cabaletta Bio(CABA.US) With Buy Rating, Maintains Target Price $13 - Moomoo
Cabaletta Bio reports phase 1/2 data for autoimmune therapy - Investing.com UK
Jefferies reiterates Cabaletta Bio stock rating on autoimmune data By Investing.com - Investing.com South Africa
CABA: Cabaletta Bio Shares Positive Clinical Updates at EULAR 20 - GuruFocus
Cabaletta Bio Highlights Rese-cel Data and Pivotal Path - TipRanks
Jefferies reiterates Cabaletta Bio stock rating on autoimmune data - Investing.com
Cabaletta Bio reports phase 1/2 data for autoimmune therapy By Investing.com - Investing.com Nigeria
Cabaletta Bio (CABA) details strong rese-cel data and pivotal plans in myositis, SSc and lupus - Stock Titan
Cabaletta Bio Announces New Rese-cel Data and Development Updates Across Autoimmune Portfolio, Including Encouraging Early PC-Free Lupus Findings, at EULAR 2026 Congress - The Manila Times
Cabaletta Bio Shares Tick Up Ahead of June Data Investors Await - Bez Kabli
Cabaletta Bio (CABA) Climbs 2.7% as Biotech Stock Tests Key Resistance Near $4.14Low Risk Entry Stocks - thelegaladvocate.com
CABA Technical Analysis | Trend, Signals & Chart Patterns | CABALETTA BIO INC (NASDAQ:CABA) - ChartMill
Finanzdaten der Cabaletta Bio Inc-Aktie (CABA)
Umsatz
Nettogewinn
Free Cashflow
ENV
Cabaletta Bio Inc-Aktie (CABA) Insiderhandel
| Insiderhandel | Beziehung | Datum | Transaktion | Kosten | #Aktien | Wert ($) | #Aktien Gesamt |
|---|---|---|---|---|---|---|---|
| Binder Gwendolyn | President, Science & Tech. |
Jan 21 '26 |
Buy |
2.19 |
11,312 |
24,763 |
31,312 |
| Tomasello Shawn | Director |
Jan 21 '26 |
Buy |
2.21 |
22,725 |
50,322 |
22,725 |
| Gavel Steve | Chief Commercial Officer |
Jan 21 '26 |
Buy |
2.27 |
22,170 |
50,215 |
22,170 |
| Bollard Catherine | Director |
Jan 21 '26 |
Buy |
2.27 |
4,405 |
9,982 |
5,405 |
| Nichtberger Steven | President & CEO |
Jan 21 '26 |
Buy |
2.24 |
45,000 |
100,778 |
1,031,483 |
| Simon Mark | Director |
Jan 21 '26 |
Buy |
2.28 |
11,061 |
25,261 |
147,205 |
| Gerard Michael | General Counsel |
Jan 21 '26 |
Buy |
2.27 |
6,600 |
14,979 |
6,600 |
1.36%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):